重组人生长激素在肠瘘伴低白蛋白血症病人中前瞻性应用研究  

A prospective study of effects of recombinated human growth hormone on intestinal fistula patients with hypoalbumemia

作　　者：尹路[1] 许宝华[1] 李维勤[1] 顾军[1] 陈昶[1] 任建安[1] 黎介寿[1] 

机构地区：[1]南京军区南京总医院解放军普通外科研究所

出　　处：《肠外与肠内营养》1998年第1期6-9,共4页Parenteral & Enteral Nutrition

摘　　要：本研究前瞻性观察重组人生长激素（ｒｅｃｏｍｂｉｎａｔｅｄｈｕｍａｎＧｒｏｗｔｈＨｏｒｍｏｎｅ，ｒｈＧＨ）在肠外瘘伴低白蛋白血症病人的作用。选择１９９５年１２月～１９９７年６月间住院的肠瘘伴低白蛋白血症（＜３０ｇ／Ｌ）病人３０例，随机分为对照组１５例和ｒｈＧＨ组１５例，重组人生长激素（瑞士，Ｓｅｒｏｎｏ产品）４Ｕ×３／ｄ，肌肉注射，连续７天。实验前（０天）、实验第４和第８天，测定病人体重、血生化、血浆蛋白。结果示（１）两组病人治疗后体重均无明显的变化（Ｐ＞０．０５），两组病人的血糖、血清肌酐、ＡＫＰ、ＡＬＴ和总胆红素亦无明显差异。（２）ｒｈＧＨ组第８天的血清白蛋白浓度（３５．４±４．５ｇ／Ｌ）显著高于治疗前（２８．７±３．０ｇ／Ｌ）（Ｐ＜０．０１），而对照组血清白蛋白浓度无显著提高（Ｐ＞０．０５）。在实验第８天ｒｈＧＨ组的血清白蛋白浓度（３５．４±４．５ｇ／Ｌ）显著高于对照组（２９．１４±３．０ｇ／Ｌ）（Ｐ＜０．０５）。（３）ｒｈＧＨ组病人治疗后血清前白蛋白浓度（４．５±１．８ｇ／Ｌ）显著高于治疗前（２．９±１．７ｇ／Ｌ）和对照组（Ｐ＜０．０１）。（４）ｒｈＧＨ组病人治疗后血清转铁蛋白浓度显著高于治疗前和对照?Objective:To study the effects of recombinated human growth hormone(rhGH) on intestinal fistula patients with hypoalbumemia. Methods:Thirty intestinal fistula patients(from Dec.1995 to Jun.1997) with hypoalbuminemia were divided randomly into two groups.Patients in the control group only received TPN for 7 days,while patients in the rhGH group received rhGH(4U×7d) and TPN for 7 days.The body weight,blood biochemistry and proteins of patients were detected. Results:There were no significant difference in body weight,blood glucose,Cr,AKP,ALP and total bilirubin between two groups.Serum albumin,prealbumin,and transferin concentrations were markedly increased in patients after rhGH treatment,while not apparent effect was observed in the control group.After experiment,serum concentrations of albumin,prealbumin,and transferin in the ghGH group were significantly higher than that of control group. Conclusions:The combination TPN and rhGH may be as a part of nutritional support,and have an important effect in prevent and treatment of hypoalbuminemia in patients with intestinal fistula.

关 键 词：肠外瘘 低白蛋白血症 并发症 RHGH 

分 类 号：R656.06[医药卫生—外科学] R591.2[医药卫生—临床医学]